Back to search results

HYPERION CCA: A Study for Advanced Intrahepatic Cholangiocarcinoma

This study is for people with advanced intrahepatic cholangiocarcinoma (a type of liver cancer). It compares standard treatment with or without liver-directed radiation therapy (L-RT). Participants will receive a combination of drugs: Durvalumab, Gemcitabine, and Cisplatin, given by IV. The main goal is to see how safe these treatments are and what side effects occur over about one year. To join, you must be over 18, weigh more than 30 kg, and have a confirmed diagnosis of intrahepatic cholangiocarcinoma with at least one tumor 3 cm or larger. The study aims to enroll 60 participants.

Study design
This is an interventional study with an unclear status, planning to enroll 60 participants. It compares outcomes for patients receiving systemic therapy with or without liver-directed radiation therapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06858735

HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma

Recruiting
PHASE2Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~60 participants
Updated 2026-03-11 on ClinicalTrials.gov
What's tested:DurvalumabGemcitabineCisplatin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Advanced Intrahepatic Cholangiocarcinoma

Explore related trials

Intrahepatic Cholangiocarcinoma

NCT06858735

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Eugene Koay, MD,PHD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Eugene Koay, MD,PHD
[email protected]
(713) 563-2381
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0